AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
企業コードABBV
会社名AbbVie Inc
上場日Jan 02, 2013
最高経営責任者「CEO」Michael (Robert A)
従業員数55000
証券種類Ordinary Share
決算期末Jan 02
本社所在地1 N Waukegan Rd
都市NORTH CHICAGO
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号60064
電話番号18479327900
ウェブサイトhttps://www.abbvie.com/
企業コードABBV
上場日Jan 02, 2013
最高経営責任者「CEO」Michael (Robert A)